ClinicalTrials.gg
CompletedNCT05855538MAESTRIAUpdated Oct 21, 2026

Clinical Cohorts for Validation of New Digital Biomarkers

An observational study in Atrial Fibrillation and Atrial Cardiomyopathy, sponsored by Atrial Fibrillation Network. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Atrial Fibrillation Network · Observational

How we know

Updated Oct 21, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
515
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Atrial Fibrillation by Atrial Fibrillation Network — 2 open to participants now, 2 under way, none of them phase 3. Atrial Fibrillation · Atrial Fibrillation Network.

Started
2023
the only one that year
Observational
3 of 13
none open now
Registered
11th of 13
by date

Among the 13 studies in Atrial Fibrillation by Atrial Fibrillation Network, this one is the only one that started in 2023, is one of 3 observational ones, and was the 11th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

2 of the 13 studies in Atrial Fibrillation by Atrial Fibrillation Network are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Atrial Fibrillation by Atrial Fibrillation Network, or all of them as a file.
02

Study summary

The MAESTRIA study is an international, multi-centre, non-interventional, observational registry. The main goal is to enrol a representative group of European patients diagnosed with Atrial Fibrillation (AF) to analyse clinical and relevant parameters (digitalised ECG, echocardiograms, cardiac CTs, MRIs and blood biomarkers) that could be used during clinical practise for the diagnosis of atrial cardiomyopathy. The AF patients will be distributed in 3 groups according to the different manifestation of AF: paroxysmal, persistent and permanent AF.

Read the detailed description

Atrial fibrillation (AF) and stroke are major health care problems in Europe. They are most often the clinical expression of atrial cardiomyopathy, which is under-recognised due to the lack of specific diagnostic tools. Multidisciplinary research and stratified approaches are urgently needed to prevent, diagnose, and treat AF and stroke and preempt the AF-related threat to healthy ageing in Europe.

MAESTRIA is a European consortium of 18 clinicians, scientists and pharma industry partners who are at the forefront of research and medical care of AF and stroke patients funded by the EU Horizon 2020 programme (grant number 965286). The Atrial Fibrillation Network (AFNET) is one of the 18 partner institutions in this European consortium.

MAESTRIA will create multi-parametric digital tools based on a new generation of biomarkers that integrate artificial intelligence (AI) processing and big data from cutting edge imaging, electrocardiography and omics technologies. It will develop novel biomarkers, diagnostic tools and personalized therapies for atrial cardiomyopathy.

The MAESTRIA-AFNET 10 Study is an integral part of the MAESTRIA project. The study will collect relevant clinical parameters for AF from patients, this includes ECGs, cardiac CTs, MRIs and echocardiograms. Dedicated core labs will collect and homogenize the clinical data.

For atrial arrhythmias (AA) and vascular stiffness index (VSI) recording, patients will be provided with a measuring bracelet for continuous monitoring of heart rhythm with a photoplethysmographic (PPG) sensor coupled with a smartphone app and the Preventicus Heartbeats® analytic service (Class IIa, CE marked), approved as consumer device. Preventicus is ISO 13485 certified.

03

Conditions studied

  • Atrial Fibrillation
  • Atrial Cardiomyopathy

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

European prospective cohort of patients with diagnosed AF.

Patients are distributed in 3 groups according to the different clinical manifestation of AF:

  1. Patients with paroxysmal AF (clinically defined as AF episodes less than one week), or
  2. Patients with persistent AF (clinically defined as AF episodes longer than one week), or
  3. Patients with permanent AF (no documented sinus rhythm or possibility to restore sinus rhythm by any means)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with paroxysmal AF, persistent AF or permanent AF.
  • Patients (or legally acceptable representative if applicable to country specific regulations) provide written to participate in the study. The patient has the option to give separate consent to donate extra volume of blood during the routine blood collection, that can be used for biomedical research.
  • Patient is at least 18 years old.
  • Patient must own a smartphone with Apple iOS version 14.5 (or higher) or with Android version 8.0 (or higher).

Exclusion criteria

Exclusion Criteria:

  • Any disease that limits to less than 1 year.
  • All persons unable to provide .
  • All persons exempt from participation in a study or trial by law.
  • Any medical or psychiatric condition which, in the investigator´s opinion, would preclude the participant from adhering to the protocol or completing the study per protocol.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
515 participants (actual)
Target follow-up
12 Months
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Paroxysmal AF

    215 patients

  • Persistent AF

    216 patients

  • Permanent AF

    84 patients

06

What researchers measure

Primary outcomes

  1. Physical examination

    Weight (Kilograms-Kg) Height (centimeters-cm) Weight and height will be combined to calculate BMI in Kg/m\^2

    Time frame: 12 months

  2. Clinically relevant changes in CT/MRI

    only if clinically indicated

    Time frame: 12 months

  3. Atrial Arrythmias (AA) burden and vascular stiffness (measured by a measuring bracelet)

    AA burden and vascular stiffness measured by the measuring bracelet

    Time frame: 12 months

  4. Cognitive function test (MoCA)

    evaluation of cognitive function (includes different tasks: visual/executive; naming; memory; attention; language; abstraction; delayed recall; orientation). Total score will be calculated and collected.

    Time frame: Baseline and Follow up at 12 months

  5. EQ-5D-5L Quality of Life questionnaire

    quality of life assessment (includes questions about mobility, self care, usual activities, pain/discomfort and anxiety/depression). The health state code will be collected (calculated as concatenation of 5 scores). Health score from vertical visual analogue scale (0-100) will be collected.

    Time frame: Baseline and Follow up at 12 months

  6. Ischaemic events (systemic, myocardial and cerebral)

    ischaemic events

    Time frame: 12 months

  7. Echo analysis (TEE_transesophageal echocardiography): LAA smoke available

    collected as Yes/No

    Time frame: 12 months

  8. Echo analysis (TEE_transesophageal echocardiography): Flow velocity in LAA

    measured in cm/sec

    Time frame: 12 months

  9. Echo analysis (TEE_transesophageal echocardiography): Antrum diameter

    measured in mm

    Time frame: 12 months

  10. Echo analysis (TTE_transthoracic echocardiography): LVEF

    Measured in %; Biplane Simpson Method

    Time frame: 12 months

  11. Echo analysis (TTE_transthoracic echocardiography): LA diameter

    measured in mm LA volume (mL) Septum thickness (mm) Degree of mitral valve insufficiency (Grade I/trivial; Grade II/moderate; Grade III/moderate to severe; Grade IV/severe; None). Degree of tricuspid valve insufficiency (Grade I/trivial; Grade II/moderate; Grade III/moderate to severe; Grade IV/severe; None).

    Time frame: 12 months

  12. Echo analysis (TTE_transthoracic echocardiography): LA volume

    measured in mL

    Time frame: 12 months

  13. Echo analysis (TTE_transthoracic echocardiography): Septum thickness

    measured in mm Degree of mitral valve insufficiency (Grade I/trivial; Grade II/moderate; Grade III/moderate to severe; Grade IV/severe; None). Degree of tricuspid valve insufficiency (Grade I/trivial; Grade II/moderate; Grade III/moderate to severe; Grade IV/severe; None).

    Time frame: 12 months

  14. Echo analysis (TTE_transthoracic echocardiography): Degree of mitral valve insufficiency

    Grade I/trivial; Grade II/moderate; Grade III/moderate to severe; Grade IV/severe; None

    Time frame: 12 months

  15. Echo analysis (TTE_transthoracic echocardiography): Degree of tricuspid valve insufficiency

    Grade I/trivial; Grade II/moderate; Grade III/moderate to severe; Grade IV/severe; None

    Time frame: 12 months

  16. ECG analysis

    Electrocardiogram analysis (paper and digital, if available). \- 12-lead body surface ECG will be collected. Variables to be collected in the eCRF: Heart Rhythm (Sinus rhythm; Atrial Fibrillation; Continuous pacing; Pacing and AF; other (specify as free text). Heart rate (beats/min) Heart axis (degrees) QRS interval (msec) PR interval (msec) P-wave duration (msec) QT-duration (msec) QTcF (msec) Other relevant ECG findings (to add as free text).

    Time frame: 12 months

  17. MRI analysis: LAEF

    Left atrial ejection fractio measured in %

    Time frame: 12 months

  18. MRI analysis: LAVi

    LAVi left atrial volume index measured in ml/m\^2

    Time frame: 12 months

  19. MRI analysis: LALRS

    LALRS left atrial longitudinal reservoir strain measured in %

    Time frame: 12 months

  20. MRI analysis: LALBS

    LALBS left atrial longitudinal booster strain measured in %

    Time frame: 12 months

  21. CT scan analysis

    The cardiac CTs will be sent to the specialised core lab for analysis. The analysis will include: Atriomic risk of stroke (5 year event risk) Yes/No

    Time frame: 12 months

Secondary outcomes

  1. CT scan: Atriomic risk for AF

    5 year event risk: Yes/No

    Time frame: 12 months

  2. CT scan: Epicardial Adipose tissue volume

    measured in cm\^3

    Time frame: 12 months

  3. CT scan: Epicardial adipose tissue mean attenuation

    measured in HU

    Time frame: 12 months

  4. CT scan: Left atrium volume

    measured in cm\^3

    Time frame: 12 months

07

Study locations

1 site
  • St Vincenz Hospital
    Paderborn, 33098, Germany
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Jul 2026, 40 months.

Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's 40 months is below that.

Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Aug 2024 → Jul 2026 and completion Aug 2025 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2023
First posted
May 11, 2023
StartActual
Mar 2, 2023
Primary completionActual
Jul 24, 2026was Aug 2024
CompletionActual
Aug 31, 2026was Aug 2025
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 21, 2026
Primary completion
Aug 2024→Jul 24, 2026 (actual)
Oct 21, 2026
Study completion
Aug 2025→Aug 31, 2026 (actual)
Oct 21, 2026
Enrollment
600 (estimated)→515 (actual)
Oct 21, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionECG analysis: how it is measured was reworded
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Recruiting→Completed
    Primary completion Aug 2024→Jul 24, 2026 (now actual)
    Study completion Aug 2025→Aug 31, 2026 (now actual)
    Enrollment 600 (estimated)→515 (actual)
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionECG analysis: how it is measured was reworded
    + 6 other changes: verification date, conditions, arm descriptions, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05855538
Lead sponsor
Atrial Fibrillation Network
Responsible party
Sponsor
First posted
May 11, 2023
Start date
Mar 2, 2023
Primary completion
Jul 24, 2026
Completion
Aug 31, 2026
Last update
Oct 21, 2026

Study contacts

Stéphane Hatem, Prof
study director · ICAN Nutrition Education and Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion